

PRELIMINARY PROGRAMME

EASL SPECIAL CONFERENCE ON HEPATOCELLULAR CARCINOMA

Dubrovnik, Croatia, June 25 - 26, 2010

THURSDAY, JUNE 24, 2010

16:00 - 19:00 Registration

20:30 **Speakers Dinner**

FRIDAY, JUNE 25, 2010

08:00 - 09:00 Registration

09:00 - 09:10 Welcome Address
Josep M. Llovet, Spain/ USA and **Jorge Marrero**, USA

09:10 - 11:00 Symposium 1: Epidemiology and Surveillance
Chairs: **Josep M. Llovet**, Spain/ USA, **Morris Sherman**, Canada

09:10 - 09:35 Risk factors and cost-benefit of surveillance programs
Morris Sherman, Canada

09:35 - 10:05 Epidemiology of HCC in developing countries
Flair Carrilho, Brazil

10:05 - 10:30 Assessment of early HCC detection in Western countries
Alejandro Forner, Spain

10:30 - 11:00 Chemoprevention of HCC in cirrhotic patients
Adrian di Bisceglie, USA

11:00 - 11:30 Coffee Break and Poster Viewing

11:30 - 13:30 Symposium 2: Signaling and Driver Oncogenes in HCC
Chairs: **Jessica Zucman-Rossi**, France, **Yujin Hoshido**, USA

11:30 - 12:00 Linking fibrosis with cancer risk: molecular perspective
Yujin Hoshida, USA

12:00 - 12:30 Critical appraisal of signaling pathways in HCC
Augusto Villanueva, Spain

12:30 - 13:00 Angiogenesis in hepatocarcinogenesis
David Semela, Switzerland

13:00 - 13:30 Genomics in HCC: tumor vs. microenvironment, where are the targets?
Snorri Thorgeirsson, USA

13:30 - 14:30 Lunch Break and Poster Viewing

14:30 - 15:15 Keynote Lecture: Milestones in the management of HCC
Massimo Colombo, Italy

- 15:15 - 17:15 Symposium 3: Diagnosis of early HCC: pathology and radiology**
Chairs: **Jorge Marrero**, USA and **Tania Roskams**, Belgium
- 15:15 - 15:45 International Consensus Group: Pathologic diagnosis
Tania Roskams, Belgium
- 15:45 - 16:15 Molecular diagnosis of HCC
Valérie Paradis, France
- 16:15 - 16:45 Review of radiologic diagnosis
Luigi Bolondi, Italy
- 16:45 - 17:15 Integrative clinical and molecular approach for diagnosis
Jorge Marrero, USA
- 17:15 - 17:45 Coffee Break and Poster Viewing**
- 17:45 - 19:45 Symposium 4: Clinical and Molecular Classification of HCC**
Chairs: **Jordi Bruix**, Spain and **Masatoshi Kudo**, Japan
- 17:45 - 18:15 Clinical Staging systems and prognosis in the West
Jordi Bruix, Spain
- 18:15 - 18:45 Clinical classification in Asia
Masatoshi Kudo, Japan
- 18:45 - 19:15 Role of TNM in HCC stratification
Ronnie Poon, China
- 19:15 - 19:45 Molecular classification and biomarkers in HCC
Jessica Zucman-Rossi, France
- 20:30 **Welcome Reception**
- SATURDAY, JUNE 26, 2010**
- 09:00 - 11:00 Symposium 5: Novel concepts in surgery for hepatocellular carcinoma**
Chairs: **Vincenzo Mazzaferro**, Italy, **Myron Schwartz**, USA
- 09:00 - 09:30 Should we expand current criteria for resection/ OLT?
Myron Schwartz, USA
- 09:30 - 10:00 Outcome after OLT: Metroticket proposal
Vincenzo Mazzaferro, Italy
- 10:00 - 10:30 Critical appraisal of LDLT in HCC after 20 years
Pierre Clavien, Switzerland
- 10:30 - 11:00 How to handle waiting times for OLT: MELD and beyond
Fabio Piscaglia, Italy

- 11:00 - 11:30 Coffee Break and Poster Viewing**
- 11:30-13:30 Symposium 6: Loco-regional approaches for hepatocellular carcinoma**
Chairs: **Masao Omata**, Japan, **Flair Carrilho**, Brazil
- 11:30 - 12:00 Future of radiofrequency in 5-10 years
Riccardo Lencioni, Italy
- 12:00 - 12:30 Novel devices for ablation, HIFU and beyond
Masao Omata, Japan
- 12:30 - 13:00 Who benefits from chemoembolization
Michael Beaugrand, France
- 13:00 - 13:30 Can internal radiation compete with TACE?
Laura Kulik, USA
- 13:30 - 14:30 Lunch Break and Poster Viewing**
- 14:30 - 16:30 Symposium 7: Current systemic therapies in HCC**
Chairs: **Josep M. Llovet**, Spain/ USA, **Ann-Li Cheng**, Taiwan
- 14:30 - 15:00 Sorafenib: Implications in management and trial design
Josep M. Llovet, Spain/USA
- 15:00 - 15:30 Who benefits most from sorafenib treatment?
Ann-Li Cheng, Taiwan
- 15:30 - 16:00 Active trials: First line and second line
Eric Raymond, France
- 16:00 - 16:30 Are there still opportunities for chemotherapy in HCC?
Tim Meyer, UK
- 16:30 - 17:00 Coffee Break and Poster Viewing**
- 17:00 - 19:00 Symposium 8: Novel Molecular therapies and Future Trials**
Chairs: **Peter Galle**, Germany, **Masao Omata**, Japan
- 17:00 - 17:30 Overview of pre-clinical data with novel drugs in HCC
Peter Galle, Germany
- 17:30 - 18:00 Novel anti-proliferative vs. Anti-angiogenic drugs
Richard Finn, USA
- 18:00 - 18:30 Is there rationale for immunomodulation?
Tim Greten, USA
- 18:30 - 19:00 Adjuvant therapies after resection / local ablation
Masao Omata, Japan
- 19:00 **Closing Ceremony**